Treatment of congenital osteopetrosis in the rabbit with high-dose 1,25-dihydroxyvitamin D
Open Access
- 1 February 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 4 (1) , 57-67
- https://doi.org/10.1002/jbmr.5650040109
Abstract
Osteopetrosis is a congenital metabolic bone disease characterized by skeletal sclerosis resulting from defective osteoclast-mediated bone resorption. Osteopetrosis has been decribed in several animal species (mouse, rat, and rabbit) and in children. Bone marrow transplantation, originally shown to reverse the skeletal sclerosis in some animal mutations, has been effective in curing osteopetrosis in some children. Unfortunately, not all children with osteopetrosis are candidates for or respond to bone marrow transplantation. Recent studies have shown that several animal mutations and some children inheriting osteopetrosis have significantly elevated serum levels of 1,25-(OH)2D. Based on the possibility that there may be a resistance to 1,25-(OH)2D, high-dose calcitriol therapy has been used to treat some children and stimulated some parameters of resorption. In this study, we have examined the effects of high-dose calcitriol therapy on various serum and skeletal parameters in the osteopetrotic rabbit. Mutant rabbits and normal littermates were given continuous infusions of calcitriol via subcutaneously implanted osmotic minipumps for 2 weeks at a dose of 0.5, 2.5, or 25 μg/kg/per day. Untreated mutant rabbits are hypocalcemic and hypophosphatemic in the presence of elevated serum 1,25-(OH)2 levels in comparison with their normal littermates. Calcitriol infusions resulted in dose-dependent increases in circulating 1,25-(OH)2D levels in both normal and mutant rabbits. However, evaluation of other serum parameters and the skeletal response demonstrated significant differences between osteopetrotic and normal rabbits. At the highest dose, normal animals rapidly became hypercalcemic and osteoporotic, accompanied by weight loss and a failure to thrive; mutants remained hypocalcemic and osteopetrotic but did not exhibit the deleterious physical effects seen in treated normal littermates. Although the number of osteoclasts increased in both mutants and normals, osteoclast phenotype in the former remained abnormal. These data indicate that although very high levels of circulating 1,25-(OH)2D were achieved in osteopetrotic mutants, activation of osteoclast-mediated bone resorption with subsequent improvement of skeletal sclerosis was not observed.Funding Information
- NIH (DE 07444 (SCM), AM 16061 (JEZ))
- NIH (DE 05461 (SNP))
This publication has 32 references indexed in Scilit:
- The osteopetrotic rabbit: Skeletal cytology and ultrastructureJournal of Anatomy, 1987
- The osteopetrotic rabbit: General and skeletal features of a new outbred stockBone, 1986
- Calcitriol for Congenital OsteopetrosisNew England Journal of Medicine, 1984
- Treatment of Congenital Osteopetrosis with High-Dose CalcitriolNew England Journal of Medicine, 1984
- ALLOGENEIC BONE-MARROW TRANSPLANTATION IN INFANTILE MALIGNANT OSTEOPETROSISThe Lancet, 1983
- Extra-renal production of 24,25-dihydroxyvitamin D in chronic renal failure during 25 hydroxyvitamin D3 therapyKidney International, 1983
- The effect of parathyroid hormone, 1,25‐dihydroxycholecalciferol and prostaglandins on the cytoplasmic activity of isolated osteoclastsxsThe Journal of Pathology, 1982
- Successful Bone-Marrow Transplantation for Infantile Malignant OsteopetrosisNew England Journal of Medicine, 1980
- Osteopetrosis in the toothless (tl) rat: Presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermatesJournal of Anatomy, 1977
- Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants.The Journal of Experimental Medicine, 1975